Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / ADR
-
Shares outstanding
-
55.6M
-
Number of holders
-
132
-
Total 13F shares, excl. options
-
47.7M
-
Shares change
-
+2.09M
-
Total reported value, excl. options
-
$5.49B
-
Value change
-
+$238M
-
Put/Call ratio
-
0.21
-
Number of buys
-
74
-
Number of sells
-
-63
-
Price
-
$115.15
Significant Holders of Ascendis Pharma A/S - ADR (ASND) as of Q2 2019
175 filings reported holding ASND - Ascendis Pharma A/S - ADR as of Q2 2019.
Ascendis Pharma A/S - ADR (ASND) has 132 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 47.7M shares
of 55.6M outstanding shares and own 85.77% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (7.18M shares), FMR LLC (4.69M shares), RA CAPITAL MANAGEMENT, LLC (4.13M shares), ORBIMED ADVISORS LLC (3.85M shares), BAKER BROS. ADVISORS LP (3.39M shares), Vivo Capital, LLC (2.06M shares), Avoro Capital Advisors LLC (1.97M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.7M shares), Artisan Partners Limited Partnership (1.59M shares), and FARALLON CAPITAL MANAGEMENT LLC (1.54M shares).
This table shows the top 132 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.